Ocuphire Pharma (NASDAQ:OCUP – Get Free Report) had its price target reduced by research analysts at Canaccord Genuity Group from $18.00 to $10.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock.
Separately, HC Wainwright cut their price target on shares of Ocuphire Pharma from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, August 15th.
View Our Latest Analysis on Ocuphire Pharma
Ocuphire Pharma Stock Performance
Ocuphire Pharma (NASDAQ:OCUP – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). Ocuphire Pharma had a negative return on equity of 30.19% and a negative net margin of 85.75%. The company had revenue of $1.11 million during the quarter, compared to the consensus estimate of $1.80 million. Equities analysts anticipate that Ocuphire Pharma will post -1.11 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Ocuphire Pharma
A number of hedge funds have recently modified their holdings of OCUP. Empowered Funds LLC purchased a new stake in Ocuphire Pharma in the 1st quarter worth $74,000. Vanguard Group Inc. raised its position in shares of Ocuphire Pharma by 6.9% during the 1st quarter. Vanguard Group Inc. now owns 992,200 shares of the company’s stock valued at $1,994,000 after buying an additional 64,400 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Ocuphire Pharma during the 1st quarter valued at about $36,000. Institutional investors own 14.97% of the company’s stock.
About Ocuphire Pharma
Ocuphire Pharma, Inc, a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances.
Further Reading
- Five stocks we like better than Ocuphire Pharma
- How to Calculate Return on Investment (ROI)
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What is the Shanghai Stock Exchange Composite Index?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Best Aerospace Stocks Investing
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Ocuphire Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocuphire Pharma and related companies with MarketBeat.com's FREE daily email newsletter.